The Zacks Analyst Blog Highlights: Gilead Sciences, Celgene, Fate Therapeutics, Exelixis and Akebia Therapeutics

A generic image of a line graph
Credit: Shutterstock photo

For Immediate Release

Chicago, IL - February 14, 2017 - announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Gilead Sciences Inc. (NASDAQ: GILD - Free Report ), Celgene Corporation ( NASDAQ: CELG - Free Report) , Fate Therapeutics, Inc. ( NASDAQ: FATE - Free Report),Exelixis, Inc. ( NASDAQ: EXEL - Free Report) and Akebia Therapeutics, Inc. ( NASDAQ: AKBA - Free Report) .

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Monday's Analyst Blog:

Forget Gilead: Buy These Biotech Stocks Instead

Biotech major, Gilead Sciences Inc. (NASDAQ: GILD - Free Report ), reported better-than-expected results for the fourth quarter of 2016 -- however, shares were down 8.6% immediately after the company reported results. Overall, Gilead's shares are down 9.3% ever since 4Q results were announced.

Moreover, over the past year, the company has underperformed the Zacks categorized Medical-Biomedical/Genetics industry with shares declining 25.7% compared to the industry decline of 2.8%.

Why Did GILD's Shares Decline?

Even though Gilead's 4Q results surpassed estimates, shares were down due to the company's 2017 guidance, which fell well short of expectations. Although a decline in sales of the company's struggling hepatitis C virus (HCV) franchise was largely expected, the magnitude of decline was more than anticipated. The HCV franchise, which delivered sales of about $14.8 billion in 2016, is expected to deliver sales of $7.5 - $9 billion this year. That's a pretty steep decline for what was once a huge revenue generator for the company. Meanwhile, overall product sales are now expected in the range of $22.5 - $24.5 billion in 2017, down from almost $30 billion in 2016.

Gilead's HCV franchise has been under pressure for quite a while now given the changing market dynamics. Gilead expects HCV treatment starts to be lower in 2017 than in 2016. The company said that total HCV treatment starts in the U.S. were about 25,000 less than in 2015.

Although Gilead's HIV franchise should do well, factors like patent expiries, competition, and lack of major product launches/near-term pipeline catalysts will remain an overhang on the shares. In such a scenario, we advise investors to forget Gilead, a Zacks Rank #4 (Sell) stock, and invest in biotech stocks which sport a strong Zacks Rank and have interesting pipelines/products and growth potential.

Our Picks

Celgene Corporation ( NASDAQ: CELG - Free Report): Summit, NJ-based Celgene is focused on the discovery, development and commercialization of innovative therapies for the treatment of cancer and inflammatory diseases. Blood cancer treatment, Revlimid, is the key contributor to the top-line and continues to deliver impressive growth. Moreover, the Zacks Rank #2 (Buy) stock has been diversifying its portfolio with other drugs like Pomalyst and Otezla -- both drugs crossed sales of $1 billion in 2016. Otezla (psoriasis, active psoriatic arthritis) has immense potential with sales being driven by demand, an expanded U.S. footprint, growing market share and launch in new markets.

Celgene has a rich and promising pipeline as well. In addition to working on expanding the labels of currently marketed products like Revlimid, Pomalyst and Otezla, the company has several late-stage candidates including ozanimod (ulcerative colitis and relapsing multiple sclerosis with regulatory filing expected by year end) and GED-0301 (Crohn's disease and ulcerative colitis) in the inflammation and immunology therapeutic area and CC-486 (myelodysplastic syndromes and acute myeloid leukemia), enasidenib (acute myeloid leukemia - regulatory application submitted in the U.S. with a decision expected in the second half of 2017) and luspatercept (myelodysplastic syndromes and beta-thalassemia) within hematology. What makes the pipeline more attractive is that quite a few of these candidates have blockbuster potential.

Celgene's price performance over the past one year shows that the company has outperformed the Zacks categorized Medical-Biomedical/Genetics industry.

Fate Therapeutics, Inc. ( NASDAQ: FATE - Free Report): San Diego, CA-based Fate is focused on the development of programmed cellular immunotherapies for cancer and immune disorders. The Zacks Rank #2 stock's immuno-oncology pipeline includes off-the-shelf NK- and T-cell cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for regulating autoimmunity. Immuno-oncology is one of the most lucrative and highly sought after therapeutic areas.

Exelixis, Inc. ( NASDAQ: EXEL - Free Report) : South San Francisco, CA-based Exelixis is focused on bringing cancer treatments to market. Approved products include Cabometyx (advanced kidney cancer), Cometriq (certain forms of thyroid cancer) and Cotellic (advanced melanoma). Cabometyx is experiencing rapid and broad uptake in the market with label expansion opportunities leaving room for upside. The company has quite a few pipeline catalysts lined up for the coming quarters.

Exelixis, a Zacks Rank #2 stock, has also outperformed the Zacks categorized Medical/Biomedical Genetics industry over the last one year.

Akebia Therapeutics, Inc. ( NASDAQ: AKBA - Free Report): Cambridge, MA-based Akebia is focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor biology. The company's lead pipeline candidate, vadadustat, is in development for the treatment of anemia related to chronic kidney disease in both non-dialysis and dialysis patients. Akebia has a collaboration and license agreement in the U.S. for vadadustat with Otsuka.

Akebia is a Zacks Rank #1 (Strong Buy) stock. You can see the complete list of today's Zacks #1 Rank stocks here .

Zacks' Best Investment Ideas for Long-Term Profit

Today you can gain access to long-term trades with double and triple-digit profit potential rarely available to the public. Starting now, you can look inside our stocks under $10, home run and value stock portfolios, plus more. Want a peek at this private information? Click here >>

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1 Stock of the Day pick for free .

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Strong Stocks that Should Be in the News

Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year. See these high-potential stocks free >>.

Get the full Report on GILD - FREE

Get the full Report on CELG - FREE

Get the full Report on FATE - FREE

Get the full Report on EXEL - FREE

Get the full Report on AKBA - FREE

Follow us on Twitter:

Join us on Facebook:

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Gilead Sciences, Inc. (GILD): Free Stock Analysis Report

Celgene Corporation (CELG): Free Stock Analysis Report

Fate Therapeutics, Inc. (FATE): Free Stock Analysis Report

Exelixis, Inc. (EXEL): Free Stock Analysis Report

Akebia Therapeutics, Inc. (AKBA): Free Stock Analysis Report

To read this article on click here.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

Learn More